UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Apple Turns 50: From Garage Startup to AI Crossroads 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
RANCHO CORDOVA, Calif., Aug. 31, 2017 -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that the Company will present at the CAR-TCR Summit 2017, which is being held September 6-7, 2017 at the Seaport Hotel & World Trade Center in Boston.
Jon Ellis, senior director of technical services at ThermoGenesis, Cesca’s device subsidiary, will deliver a spotlight presentation on ThermoGenesis’ automated CAR-T cell manufacturing capabilities on Thursday, September 7, 2017 at 10:40am ET during the “Tech Slam at the Innovation Hub.”
The CAR-TCR Summit brings together over 60 world-class speakers and more than 500 cell therapy experts in the only end-to-end conference dedicated to successfully bringing the next generation CAR-T & TCR cell immunotherapies to market. For more information, please visit http://car-tcr-summit.com.
About Cesca Therapeutics Inc.
Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Cesca is also leveraging its proprietary AutoXpress® technology platform to develop autologous stem cell-based therapies that address significant unmet needs in the vascular, cardiology and orthopedic markets.
Forward-Looking Statement
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics’ annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
Company Contact: Cesca Therapeutics Inc. Wendy Samford 916-858-5191 [email protected] Investor Contact: Rx Communications Paula Schwartz 917-322-2216 [email protected]
